.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,642,268

« Back to Dashboard

Claims for Patent: 7,642,268

Title:Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
Abstract:The invention relates to a crystalline micronisate of (1 .alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)-7-[(hydroxydi-2-thienylacetyl)o- xy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0.sup.2,4]nonane-bromide, processes for preparing it and its use for preparing a pharmaceutical composition, particularly for preparing a pharmaceutical composition with an anticholinergic activity.
Inventor(s): Bender; Helmut (Wiesbaden, DE), Graebner; Hagen (Ingelheim, DE), Schindler; Konrad (Ingelheim am Rhein, DE), Trunk; Michael (Ingelheim, DE), Walz; Michael (Bingen am Rhein, DE)
Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim am Rhein, DE)
Application Number:11/532,716
Patent Claims: 1. A pharmaceutical composition, comprising crystalline tiotropium bromide micronisate characterised by a particle size X.sub.50 of between 1.0 .mu.m and 3.5 .mu.m at a Q.sub.(5.8) value of more than 60%, by a specific surface value in the range between 2 m.sup.2/g and 5 m.sup.2/g, by a specific heat of solution of more than 65 Ws/g and by a water content from about 1% to about 4.5%, wherein the crystalline tiotropium bromide micronisate is obtained from crystalline tiotropium bromide monohydrate, which crystalline tiotropium bromide monohydrate when thermally analysed by DSC has an endothermic maximum at 230.+-.5.degree. C. at a heating rate of 10K/min, has an IR spectrum which has bands inter alia at wavelengths 3570, 3410, 3105, 1730, 1260, 1035 and 720 cm.sup.-1 and which is characterised by a simple monoclinic cell with the following dimensions: a=18.0774 .ANG., b=11.9711 .ANG., c=9.9321 .ANG., .beta.=102.691.degree., V =2096.96 .ANG..sup.3; in admixture with at least one physiologically acceptable excipient.

2. The pharmaceutical composition according to claim 1, characterised in that it is an inhalable powder.

3. The pharmaceutical composition which is an inhalable powder according to claim 2, characterised in that it contains at least about 0.03% of tiotropium bromide micronisate in admixture with the physiologically acceptable excipient and further characterised in that the excipient consists of a mixture of coarser excipient with an average particle size of 15 to 80 .mu.m and finer excipient with an average particle size of 1 to 9 .mu.m, wherein the proportion of finer excipient in the total quantity of excipient is from 1 to 20%.

4. The pharmaceutical composition which is an inhalable powder according to claim 3, characterised in that it contains between about 0.05 and about 1%, of tiotropium bromide micronisate.

5. The pharmaceutical composition which is an inhalable powder according to claim 4, characterised in that the excipient consists of a mixture of coarser excipient with an average particle size of 17 to 50 .mu.m and finer excipient with an average particle size of 2 to 8.mu.m.

6. The pharmaceutical composition which is an inhalable powder according to claim 3, characterised in that the proportion of finer excipient in the total quantity of excipient is from about 3 to about 15%.

7. The pharmaceutical composition which is an inhalable powder according to claim 3, characterised in that monosaccharides, disaccharides, oligo- and polysaccharides, polyalcohols, salts or mixtures of these excipients with one another may be used as excipients.

8. The pharmaceutical composition which is an inhalable powder according to claim 7, characterised in that glucose, arabinose, lactose, saccharose, maltose, trehalose, dextrane, sorbitol, mannitol, xylitol, sodium chloride, calcium carbonate or mixtures of these excipients with one another may be used as excipients.

9. The pharmaceutical composition which is an inhalable powder according to claim 8, characterised in that glucose or lactose or mixtures of these excipients with one another may be used as excipients.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc